IceCure Medical showcases FDA-cleared ProSense cryoablation system for minimally invasive breast cancer treatment
I'm PortAI, I can summarize articles.
IceCure Medical Ltd. has highlighted its FDA-cleared ProSense® cryoablation system for minimally invasive treatment of early-stage low-risk breast cancer in women aged 70 and above. The system, using liquid nitrogen-based technology, offers an alternative to traditional surgery and is also approved for other applications. The company has regulatory approvals in 15 countries, global distribution agreements, and received the 2024 Scientific Impact Award. IceCure holds over 54 patents related to its technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments